Kymera Investor Presentation Deck

Mean (± SE) Percent IRAK4 Change from Baseline 50 -20 -40 -60 -80 -100 ● ● ● KT-474 Healthy Volunteer Study: Robust and Sustained IRAK4 Degradation Leading to Broad Cytokine Impact 1 2 3 4 KYMERA Mean % Reduction of IRAK4 (Daily oral doses for 14 days) 7 Dosing period 14 Day 17 21 Detected by mass spectrometry in circulating PBMC Steady state IRAK4 reduction achieved between Days 7 and 14 Recovery towards baseline by Day 28 (2 weeks after last dose) 50-200 mgs approached Lower Limit of Quantitation (LLOQ) ©2023 KYMERA THERAPEUTICS, INC. Placebo 25 mg QD 50 mg QD 100 mg QD 200 mg QD 28 Ex Vivo Inhibition of 9 Disease-Relevant Cytokines, Day 7-14 R848 (TLR7/8) Stimulation Placebo (n = 9) 50 mg QD (n = 9) Mean (+SE) Maximum % Change from Baseline at Day 7 - 14 100 mg QD. (n = 8-9*) Pbo 50 mg QD 200 100 -50 -100 IFNY >500% -62% IL18 IL6 15% -59% 35% -18% IL8 IL10 -5% -28% -23% 2% 100 mg -85% -68% -53% -32% -50% QD Mean values > 200% have been replaced by 200 for visualization purposes *n=8 for LPS, n=9 for R848 IL12 3% -58% -72% IL17 107% -24% -46% IRAK4 MAD TNFa -7% -21% -59% PAGE 11

View entire presentation